http://media.peerviewpress.com/000136/podcast/pvi/xml/oncology_audio.xml Wed, 06 Jan 2010 15:56:05 -0500 PVI, PeerView Institute for Medical Education http://www.peerviewpress.com Podcast Maker v1.3.8b - http://www.lemonzdream.com/podcastmaker Thought leader perspectives on current clinical advances in medicine PeerView Press is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. 2007 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://podcast.peerviewpress.com/oncology/podcast_oncologyCME-CNE-CPE_144.jpg http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Oncology no PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://podcast.peerviewpress.com/oncology/PPVNE06139e29.mp3 Fri, 18 Dec 2009 14:45:22 -0500 Science, Medicine no 00:22:17 difficult-to-treat, advanced breast cancer, triple negative, PARP inhibitors, epothilones, antiangiogenics, microtubule-targeting agents, chemotherapy-refractory PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PPVNE06139CMEinfo.pdf Fri, 18 Dec 2009 14:45:19 -0500 Science, Medicine no 00:00:00 difficult-to-treat, advanced breast cancer, triple negative, PARP inhibitors, epothilones, antiangiogenics, microtubule-targeting agents, chemotherapy-refractory PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://podcast.peerviewpress.com/oncology/PPVNE06176r68.mp3 Thu, 17 Dec 2009 15:40:46 -0500 Science, Medicine no 00:35:19 Re-Evaluating Therapeutic Options for the Prevention and Management of CINV PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PPVNE06176CMEinfo.pdf Thu, 17 Dec 2009 15:40:43 -0500 Science, Medicine no 00:00:00 Re-Evaluating Therapeutic Options for the Prevention and Management of CINV PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://podcast.peerviewpress.com/oncology/PPVNE06250e28.mp3 http://podcast.peerviewpress.com/oncology/Audio_Podcast_Audio_PPVNE06250.mp3 Thu, 10 Dec 2009 10:43:46 -0500 Science, Medicine no 00:30:16 NSCLC, lung cancer, maintenance, pemetrexed, cetuximab, erlotinib, targeted, cytotoxic, JMEN, treatment break PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PPVNE06250CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PPVNE06250_Podcast_QAApp_101209.pdf Thu, 10 Dec 2009 10:43:24 -0500 Science, Medicine no 00:00:00 NSCLC, lung cancer, maintenance, pemetrexed, cetuximab, erlotinib, targeted, cytotoxic, JMEN, treatment break PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://podcast.peerviewpress.com/oncology/PPVNE05919r79.mp3 Thu, 19 Nov 2009 13:59:52 -0500 Science, Medicine no 00:14:17 CRC, colorectal cancer, bevacizumab, cetuximab, panitumumab, EGFR, oxaliplatin, FOLFOX, FOLFIRI, irinotecan PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PPVNE05919CMEinfo.pdf Thu, 19 Nov 2009 13:59:46 -0500 Science, Medicine no 00:00:00 CRC, colorectal cancer, bevacizumab, cetuximab, panitumumab, EGFR, oxaliplatin, FOLFOX, FOLFIRI, irinotecan PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://podcast.peerviewpress.com/oncology/PPVNE06218hcc.mp3 http://podcast.peerviewpress.com/oncology/PPVNE06218hcc.mp3 Thu, 12 Nov 2009 14:39:24 -0500 Science, Medicine no 01:31:36 hepatocellular carcinoma, HCC, liver cancer, imaging tools, biomarkers, TACE, targeted therapy, multidisciplinary management PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PPVNE06218CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PPVNE06218CMEinfo.pdf Thu, 12 Nov 2009 14:39:19 -0500 Science, Medicine no 00:00:00 hepatocellular carcinoma, HCC, liver cancer, imaging tools, biomarkers, TACE, targeted therapy, multidisciplinary management PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the rationale for studying maintenance therapy in NSCLC settings and the clinical implications of new data on the maintenance use of active cytotoxic agents and targeted therapy in patients with advanced NSCLC. http://podcast.peerviewpress.com/oncology/PPVNE05904r67.mp3 http://podcast.peerviewpress.com/oncology/PPVNE05904r67.mp3 Fri, 25 Sep 2009 14:51:18 -0400 Science, Medicine no 00:14:52 maintenance, NSCLC, lung cancer, cytotoxic, JMEN, Fidias, nonsquamous, squamous, histology, erlotinib, advanced PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PPVNE05904CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PPVNE05904CMEinfo.pdf Fri, 25 Sep 2009 14:51:15 -0400 Science, Medicine no 00:00:00 maintenance, NSCLC, lung cancer, cytotoxic, JMEN, Fidias, nonsquamous, squamous, histology, erlotinib, advanced PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts provide recommendations for management of disease- and treatment-related complications in multiple myeloma. In the 3 presentations, issues related to thrombosis, neuropathy, and myeloma bone disease are discussed. http://podcast.peerviewpress.com/oncology/PA04348FCr66.mp3 http://podcast.peerviewpress.com/oncology/PA04348FCr66.mp3 Mon, 21 Sep 2009 15:16:50 -0400 Science, Medicine no 00:27:28 peripheral neuropathy, bortezomib, multiple myeloma, DVT, bone disease, vincristine, VTE, LMWH PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04348FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04348FCCMEinfo.pdf Mon, 21 Sep 2009 15:16:47 -0400 Science, Medicine no 00:00:00 peripheral neuropathy, bortezomib, multiple myeloma, DVT, bone disease, vincristine, VTE, LMWH PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest clinical trial data on the use of maintenance therapy, the clinical role of biomarkers in selecting the most appropriate therapy, and the potential of novel agents and combination strategies for advanced lung cancer. http://podcast.peerviewpress.com/oncology/PA05722FCs143.mp3 http://podcast.peerviewpress.com/oncology/PA05722FCs143.mp3 Tue, 08 Sep 2009 15:09:27 -0400 Science, Medicine no 00:34:29 NSCLC, lung cancer, histology, PFS, pemetrexed, nonsquamous, squamous, EGFR, JMEN, SATURN, Fidias PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05722FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05722FCCMEinfo.pdf Tue, 08 Sep 2009 15:09:26 -0400 Science, Medicine no 00:00:00 NSCLC, lung cancer, histology, PFS, pemetrexed, nonsquamous, squamous, EGFR, JMEN, SATURN, Fidias PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in CML management discuss the nature of higher risk CML and the current controversies over the criteria that define accelerated-phase and blast-crisis disease. In addition, the faculty will review the currently recommended treatment options for these patient populations and discuss the changed role of tyrosine kinase inhibitor (TKI) therapy in this more advanced setting. http://podcast.peerviewpress.com/oncology/PA05790FCe24.mp3 http://podcast.peerviewpress.com/oncology/PA05790FCe24.mp3 Mon, 17 Aug 2009 13:42:34 -0400 Science, Medicine no 00:26:18 chronic myeloid leukemia, CML, TKI, targeted therapy, blast, chronic, accelerated, phase, imatinib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05790FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05790FCCMEinfo.pdf Mon, 17 Aug 2009 13:42:32 -0400 Science, Medicine no 00:00:00 chronic myeloid leukemia, CML, TKI, targeted therapy, blast, chronic, accelerated, phase, imatinib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert discusses the latest clinical trial data on targeted therapies for upfront treatment of metastatic RCC, assesses the clinical implications of these data, and provides recommendations for optimal integration of new agents into the current treatment paradigm for advanced RCC. http://podcast.peerviewpress.com/oncology/PPVNE05963s142.mp3 http://podcast.peerviewpress.com/oncology/PPVNE05963s142.mp3 Wed, 12 Aug 2009 15:34:59 -0400 Science, Medicine no 00:15:31 renal cell carcinoma, RCC, bevacizumab, sunitinib, sorafenib, interferon, VEGF, TKI, pazopanib, ASCO PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PPVNE05963CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PPVNE05963CMEinfo.pdf Wed, 12 Aug 2009 15:34:56 -0400 Science, Medicine no 00:00:00 renal cell carcinoma, RCC, bevacizumab, sunitinib, sorafenib, interferon, VEGF, TKI, pazopanib, ASCO PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this educational activity, 3 clinical experts in NSCLC discuss the current state and potential future directions of targeted therapy for the treatment of this disease in its advanced stages. Highlights of this discussion include the integration of these therapies into first-line treatment and maintenance regimens for advanced NSCLC, emerging molecular targeted agents for recurrent/refractory disease, and the application of predictive and prognostic markers as well as other patient-specific and disease-related characteristics for treatment selection in patients with this malignancy. http://podcast.peerviewpress.com/oncology/PA05538FCe20.mp3 http://podcast.peerviewpress.com/oncology/PA05538FCe20.mp3 Tue, 11 Aug 2009 15:26:34 -0400 Science, Medicine no 00:34:43 non small cell lung cancer, NSCLC, gemcitabine, bevacizumab, cisplatin, pemetrexed, FLEX, erlotinib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05538FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05538FCCMEinfo.pdf Tue, 11 Aug 2009 15:26:31 -0400 Science, Medicine no 00:00:00 non small cell lung cancer, NSCLC, gemcitabine, bevacizumab, cisplatin, pemetrexed, FLEX, erlotinib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, a panel of experts evaluates the latest data on new targeted and cytotoxic treatment options for ovarian cancer (OC), and debates key issues, controversies, and challenges related to management of patients with OC. http://podcast.peerviewpress.com/oncology/PPVNE05890e030.mp3 http://podcast.peerviewpress.com/oncology/PPVNE05890e030.mp3 Tue, 04 Aug 2009 14:19:01 -0400 Science, Medicine no 00:25:09 ovarian, gynecologic cancer, bevacizumab, antiangiogenesis, CA-125, BRCA, bowel perforation, PLD, platinum resistance PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PPVNE05890CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PPVNE05890CMEinfo.pdf Tue, 04 Aug 2009 14:18:58 -0400 Science, Medicine no 00:00:00 ovarian, gynecologic cancer, bevacizumab, antiangiogenesis, CA-125, BRCA, bowel perforation, PLD, platinum resistance PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest clinical trial data on targeted and other new therapies for glioblastoma multiforme, assess the clinical implications of these data, and review some of the key ongoing studies that clinicians and patients should be aware of. http://podcast.peerviewpress.com/oncology/PPVNE05931s554.mp3 http://podcast.peerviewpress.com/oncology/PPVNE05931s554.mp3 Fri, 24 Jul 2009 14:45:54 -0400 Science, Medicine no 00:17:37 glioblastoma multiforme, GBM, bevacizumab, temozolomide, radiation, VEGF inhibitor, mTOR, irinotecan, antiangiogenic, immunostimulation PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PPVNE05931CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PPVNE05931CMEinfo.pdf Fri, 24 Jul 2009 14:45:35 -0400 Science, Medicine no 00:00:00 glioblastoma multiforme, GBM, bevacizumab, temozolomide, radiation, VEGF inhibitor, mTOR, irinotecan, antiangiogenic, immunostimulation PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in CLL management discusses the elements of high-risk CLL and the appropriate assessment of poor-prognosis features leading to optimal therapy selection in both the upfront and relapsed/refractory setting. Treatment decisions in unsymptomatic and progressive disease will be explored, and the management of elderly individuals will also be considered. http://podcast.peerviewpress.com/oncology/PA05757FCp155.mp3 http://podcast.peerviewpress.com/oncology/PA05757FCp155.mp3 Thu, 16 Jul 2009 16:08:03 -0400 Science, Medicine no 00:23:46 high-risk, chronic lymphocytic leukemia, CLL, elderly, relapsed, refractory, upfront, alemtuzumab, fludarabine PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05757FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05757FCCMEinfo.pdf Thu, 16 Jul 2009 16:08:00 -0400 Science, Medicine no 00:00:00 high-risk, chronic lymphocytic leukemia, CLL, elderly, relapsed, refractory, upfront, alemtuzumab, fludarabine PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in oncology discuss the latest data on current and emerging therapies for advanced renal cell carcinoma. http://podcast.peerviewpress.com/oncology/PA05679FCs545.mp3 http://podcast.peerviewpress.com/oncology/PA05679FCs545.mp3 Wed, 15 Jul 2009 16:01:29 -0400 Science, Medicine no 00:23:35 renal cell carinoma, RCC, AVOREN, CALGB, bevacizumab, interferon, TKI, pazopanib, sunitinib, AV-951 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05679FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05679FCCMEinfo.pdf Wed, 15 Jul 2009 16:01:23 -0400 Science, Medicine no 00:00:00 renal cell carinoma, RCC, AVOREN, CALGB, bevacizumab, interferon, TKI, pazopanib, sunitinib, AV-951 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in colorectal cancer (CRC) discusses the clinical implications of new and breaking data on the role of targeted agents as adjuvant therapy in early-stage CRC and the potential development of prognostic and predictive factors. http://podcast.peerviewpress.com/oncology/PA05724FCs553.mp3 http://podcast.peerviewpress.com/oncology/PA05724FCs553.mp3 Thu, 09 Jul 2009 15:28:42 -0400 Science, Medicine no 00:13:36 colorectal cancer, early-stage CRC, targeted, antiangiogenic therapy, bevacizumab, FOLFOX, biomarkers, high microsatellite instability, oxaliplatin, oral fluoropyrimidines PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05724FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05724FCCMEinfo.pdf Thu, 09 Jul 2009 15:28:37 -0400 Science, Medicine no 00:00:00 colorectal cancer, early-stage CRC, targeted, antiangiogenic therapy, bevacizumab, FOLFOX, biomarkers, high microsatellite instability, oxaliplatin, oral fluoropyrimidines PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in breast cancer discusses how to approach the management of a patient with metastatic HER2-positive breast cancer throughout the disease course. This program follows a patient scenario to help improve oncologists' understanding of the current standards of care and increase their awareness of emerging clinical trends in HER2-positive advanced breast cancer. http://podcast.peerviewpress.com/oncology/PA04959FCr450.mp3 http://podcast.peerviewpress.com/oncology/PA04959FCr450.mp3 Wed, 08 Jul 2009 14:27:44 -0400 Science, Medicine no 00:22:03 HER2, metastatic breast cancer, IHC, FISH, Oncotype, HERmark, endocrine therapy PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04959FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA4959FCCMEinfo.pdf Wed, 08 Jul 2009 14:27:41 -0400 Science, Medicine no 00:00:00 HER2, metastatic breast cancer, IHC, FISH, Oncotype, HERmark, endocrine therapy PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest advances in the treatment of multiple myeloma, with a focus on appropriate and clinically relevant endpoints for assessing the benefit of new therapies, and results of recent clinical trials to determine if these newer agents have convincingly demonstrated improvements in efficacy. http://podcast.peerviewpress.com/oncology/PA05541FCr440.mp3 http://podcast.peerviewpress.com/oncology/PA05541FCr440.mp3 Thu, 02 Jul 2009 16:19:13 -0400 Science, Medicine no 00:23:51 multiple myeloma, endpoints, bortezomib, cytogenetics, VAD, ASCT, dexamethasone, lenalidomide. ASH, ASCO PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05541FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05541FCCMEinfo.pdf Thu, 02 Jul 2009 16:19:10 -0400 Science, Medicine no 00:00:00 multiple myeloma, endpoints, bortezomib, cytogenetics, VAD, ASCT, dexamethasone, lenalidomide. ASH, ASCO PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. This 2-part activity focuses on some of the practical aspects of chronic pain management. Highlights from the first part of the activity include the various definitions, types, and characteristics of chronic pain. Considerations for the management of special populations with chronic pain are also discussed. The second part of the activity emphasizes the importance of patient communication, summarizes therapeutic modalities, details the rationale and challenges associated with the interdisciplinary management of chronic pain, and provides strategies for physicians when this approach is not feasible. http://podcast.peerviewpress.com/oncology/PA05601FCe028.mp3 http://podcast.peerviewpress.com/oncology/PA05601FCe028.mp3 Thu, 25 Jun 2009 15:22:29 -0400 Science, Medicine no 00:23:32 chronic pain, pain, pain management, neuropathy PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. http://podcast.peerviewpress.com/oncology/PA05601FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05601FCCMEinfo.pdf Thu, 25 Jun 2009 15:22:25 -0400 Science, Medicine no 00:00:00 chronic pain, pain, pain management, neuropathy PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in multiple myeloma bone health management discuss the development and clinical impact of myeloma bone disease and the identification of several promising therapeutic targets within the bone microenvironment. Several other topics will be addressed, including the current recommendations for bone disease assessment and management, as well as the potential role of novel therapies with bone protective aspects. http://podcast.peerviewpress.com/oncology/PA05569FCr447.mp3 http://podcast.peerviewpress.com/oncology/PA05569FCr447.mp3 Fri, 22 May 2009 15:48:00 -0400 Science, Medicine no 00:24:11 multiple myeloma bone disease, MBD, bisphosphonates, zoledronic acid, RANK Ligand, ACE, activin PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05569FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05569FCCMEinfo.pdf Fri, 22 May 2009 15:47:57 -0400 Science, Medicine no 00:00:00 multiple myeloma bone disease, MBD, bisphosphonates, zoledronic acid, RANK Ligand, ACE, activin PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in MCL discusses the characteristics of this relatively rare and clinically challenging disease, including its natural course and typical unresponsiveness to most front-line treatment options. The nature of resistant disease will also be profiled, and the activity of a novel generation of therapeutics in previously treated patients will be evaluated. http://podcast.peerviewpress.com/oncology/PA05230FCn208.mp3 http://podcast.peerviewpress.com/oncology/PA05230FCn208.mp3 Wed, 13 May 2009 10:17:58 -0400 Science, Medicine no 00:18:52 mantle cell lymphoma, MCL, CVAD, rituximab, everolimus, mTOR, PINNACLE, bortezomib, temsirolimus, ASH PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05230FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05230FCCMEinfo.pdf Wed, 13 May 2009 10:17:56 -0400 Science, Medicine no 00:00:00 mantle cell lymphoma, MCL, CVAD, rituximab, everolimus, mTOR, PINNACLE, bortezomib, temsirolimus, ASH PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss recent advances in the management of kidney cancer. Latest data on new and emerging targeted treatment options will be evaluated, treatment options for RCC with sarcomatoid features will be discussed, and an evidence-based treatment algorithm for optimal integration of targeted agents into the current treatment paradigm will be provided. Additionally, research findings from studies aiming to refine the treatment of RCC will be highlighted, including those assessing the potential role of new prognostic models, clinical and genotypic variations that might influence or predict the development of toxicities associated with targeted therapies, and strategies for prevention or overcoming treatment resistance. http://podcast.peerviewpress.com/oncology/PA05349FCs515.mp3 http://podcast.peerviewpress.com/oncology/PA05349FCs515.mp3 Mon, 11 May 2009 14:41:39 -0400 Science, Medicine no 00:20:24 renal carcinoma, RCC, bevacizumab, everolimus, sorafenib, sunitnib, TKI, AV-951, VEGF, prognostic models PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05349FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05349FCCMEinfo.pdf Mon, 11 May 2009 14:41:37 -0400 Science, Medicine no 00:00:00 renal carcinoma, RCC, bevacizumab, everolimus, sorafenib, sunitnib, TKI, AV-951, VEGF, prognostic models PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in the management of adults with hemophilia and inhibitors discuss the diagnosis and treatment of allo- and autoantibodies, as well as future directions for managing patients with hemophilia and inhibitors. http://podcast.peerviewpress.com/oncology/PA05327FCe027.mp3 http://podcast.peerviewpress.com/oncology/PA05327FCe027.mp3 Thu, 30 Apr 2009 14:24:33 -0400 Science, Medicine no 00:54:23 hemophilia, hemophilia inhibitors, hemophilia treatment, alloantibodies, autoantibodies PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. http://podcast.peerviewpress.com/oncology/PA05327FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05327FCCMEinfo.pdf Thu, 30 Apr 2009 14:24:29 -0400 Science, Medicine no 00:00:00 hemophilia, hemophilia inhibitors, hemophilia treatment, alloantibodies, autoantibodies PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in CRC management discusses contrasting approaches to treating elderly individuals presenting with advanced disease. Two case scenarios will illustrate how therapeutic decision-making may be influenced by patient health and performance status or a patients? willingness to pursue aggressive treatment. In addition, the clinical consequences of specific comorbidities or tumor-related factors will also be explored. http://podcast.peerviewpress.com/oncology/PA05540FCp153.mp3 http://podcast.peerviewpress.com/oncology/PA05540FCp153.mp3 Wed, 29 Apr 2009 16:14:28 -0400 Science, Medicine no 00:21:40 metastatic CRC, FOLFOX, FOLFIRI, elderly, performance status, CapeOX, bevacizumab, 5-FU, panitumumab, KRAS PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05540FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05540FCCMEinfo.pdf Wed, 29 Apr 2009 16:14:26 -0400 Science, Medicine no 00:00:00 metastatic CRC, FOLFOX, FOLFIRI, elderly, performance status, CapeOX, bevacizumab, 5-FU, panitumumab, KRAS PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in iron overload discusses the differences between hereditary and transfusional hemochromatosis, and evaluates the role of iron chelation in the management of the latter, including both single-agent and combination approaches. New data on the ability of chelators to reduce cardiac iron burden in patients with transfusional iron overload are also discussed. http://podcast.peerviewpress.com/oncology/PA05130FCn202.mp3 http://podcast.peerviewpress.com/oncology/PA05130FCn202.mp3 Wed, 22 Apr 2009 11:38:43 -0400 Science, Medicine no 00:23:04 hemochramatosis, chelator, iron overload, MDS, transfusion, transferrin, thalassemia, deferiprone, deferoxamine PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05130FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05130FCCMEinfo.pdf Wed, 22 Apr 2009 11:38:40 -0400 Science, Medicine no 00:00:00 hemochramatosis, chelator, iron overload, MDS, transfusion, transferrin, thalassemia, deferiprone, deferoxamine PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in breast cancer discuss current evidence on the risk of cardiotoxicity associated with various breast cancer therapies and provide practical recommendations for preventing, monitoring and managing cardiovascular adverse effects in patients undergoing treatment for breast cancer. http://podcast.peerviewpress.com/oncology/PA05378FCr430.mp3 http://podcast.peerviewpress.com/oncology/PA05378FCr430.mp3 Mon, 06 Apr 2009 15:02:01 -0400 Science, Medicine no 00:20:45 breast cancer, cardiotoxicity, trastuzumab, HERA, CHF, hypertension, cardiac events, LVEF, anthracyclines PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05378FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05378FCCMEinfo.pdf Mon, 06 Apr 2009 15:01:59 -0400 Science, Medicine no 00:00:00 breast cancer, cardiotoxicity, trastuzumab, HERA, CHF, hypertension, cardiac events, LVEF, anthracyclines PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts on breast cancer provide a concise summary of the latest and most clinically relevant data on endocrine therapies for breast cancer, and discuss how to integrate this information into everyday patient care. http://podcast.peerviewpress.com/oncology/PA05150FCs512.mp3 http://podcast.peerviewpress.com/oncology/PA05150FCs512.mp3 Thu, 02 Apr 2009 14:50:48 -0400 Science, Medicine no 00:34:47 breast cancer, endocrine therapy, aromatase inhibitors, tamoxifen, SABCS, bone loss, predictive markers PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05150FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05150FCCMEinfo.pdf Thu, 02 Apr 2009 14:50:45 -0400 Science, Medicine no 00:00:00 breast cancer, endocrine therapy, aromatase inhibitors, tamoxifen, SABCS, bone loss, predictive markers PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this program, an expert on kidney cancer provides a concise summary of the key aspects of the biology of renal cell carcinoma (RCC), characteristics of the targeted therapies, and strategies to effectively manage the adverse effects related to these agents. http://podcast.peerviewpress.com/oncology/PA05122FCn205.mp3 http://podcast.peerviewpress.com/oncology/PA05122FCn205.mp3 Tue, 10 Mar 2009 16:13:46 -0400 Science, Medicine no 00:18:59 renal cell, targeted, kidney, RCC, mTOR, antiangiogenesis, bevacizumab, sunitinib, everolimus, temsirolimus, sorafenib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05122FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05122FCCMEinfo.pdf Tue, 10 Mar 2009 16:13:43 -0400 Science, Medicine no 00:00:00 renal cell, targeted, kidney, RCC, mTOR, antiangiogenesis, bevacizumab, sunitinib, everolimus, temsirolimus, sorafenib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Experts in MDS and AML discuss the clinical importance of new findings in these settings, specifically the following topics: an evaluation of modified induction/consolidation chemotherapy in AML, an update on epigenetic treatment and the potential of epigenetic combinations to augment activity in MDS and AML, and the relevance of newer prognostic models to a well-rounded clinical approach. Faculty will also discuss new data on the mechanisms of epigenetic agents, and whether these data possess prognostic or predictive implications. http://podcast.peerviewpress.com/oncology/PA05351FCs514.mp3 http://podcast.peerviewpress.com/oncology/PA05351FCs514.mp3 Tue, 03 Mar 2009 15:09:44 -0500 Science, Medicine no 00:39:11 MDS, AML, hematologic malignancies, ASH 2008, methylation, HDAC inhibitors, epigenetics PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05351FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05351FCCMEinfo.pdf Tue, 03 Mar 2009 15:09:42 -0500 Science, Medicine no 00:00:00 MDS, AML, hematologic malignancies, ASH 2008, methylation, HDAC inhibitors, epigenetics PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this program, an expert on brain tumors discusses the current perspectives and latest advances in the treatment of glioblastoma multiforme (GBM). Evidence-based guidelines for newly diagnosed as well as recurrent GBM are reviewed and analyzed, and recommendations for how to apply them in everyday practice are provided. Additionally, up-to-date data on novel therapies are evaluated, and ongoing clinical trials assessing some of the more promising emerging therapies are highlighted. These topics are discussed in the context of results from a survey of United States–based oncologists and neurosurgeons that was conducted to assess their knowledge of and approaches to treatment of GBM. http://podcast.peerviewpress.com/oncology/PA05377FCn199.mp3 http://podcast.peerviewpress.com/oncology/PA05377FCn199.mp3 Fri, 23 Jan 2009 14:52:57 -0500 Science, Medicine no 00:20:44 GBM, glioblastoma multiforme, cytoreductive surgery, radiotherapy, temozolomide, nitrosourea, irinotecan, bevacizumab, brain, CNS PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05377FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05377FCCMEinfo.pdf Fri, 23 Jan 2009 14:52:55 -0500 Science, Medicine no 00:00:00 GBM, glioblastoma multiforme, cytoreductive surgery, radiotherapy, temozolomide, nitrosourea, irinotecan, bevacizumab, brain, CNS PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE information. In this program, an expert summarizes current evidence on prognostic and predictive factors in gastrointestinal stromal tumors (GIST), discusses when and how to use mutational analysis in clinical practice, and reviews novel agents and combinations being evaluated in the advanced disease, as well as the emerging role of targeted therapies in patients with early stage GIST. http://podcast.peerviewpress.com/oncology/PA05290FCn201.mp3 http://podcast.peerviewpress.com/oncology/PA05290FCn201.mp3 Thu, 15 Jan 2009 10:45:16 -0500 Science, Medicine no 00:32:00 GIST, KIT, PDGFRA, imatinib, TKI, sunitinib, sorafenib, bevacizumab, recurrence, kinase PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05290FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05290FCCMEinfo.pdf Thu, 15 Jan 2009 10:44:16 -0500 Science, Medicine no 00:00:00 GIST, KIT, PDGFRA, imatinib, TKI, sunitinib, sorafenib, bevacizumab, recurrence, kinase PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, an expert in non-small-cell lung cancer (NSCLC) highlights key clinical data presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. Topics of discussion include the potential impact of maintenance therapy on the current NSCLC treatment paradigm, emerging combination regimens and agents for the management of this disease, and the clinical utility of biomarker analysis and tumor cell histology for treatment selection in patients with this malignancy. http://podcast.peerviewpress.com/oncology/PA05133FCn203.mp3 http://podcast.peerviewpress.com/oncology/PA05133FCn203.mp3 Tue, 30 Dec 2008 15:23:17 -0500 Science, Medicine no 00:21:55 NSCLC, CMSTO, EGFR, bevacizumab, erlotinib, gefitinib, pemetrexed, FLEX, BMS009 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05133FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05133FCCMEinfo.pdf Tue, 30 Dec 2008 15:23:14 -0500 Science, Medicine no 00:00:00 NSCLC, CMSTO, EGFR, bevacizumab, erlotinib, gefitinib, pemetrexed, FLEX, BMS009 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, an expert in oncology discusses the current and emerging role of mTOR inhibitors in renal cell carcinoma and other solid tumors. http://podcast.peerviewpress.com/oncology/PA05278FCn200.mp3 http://podcast.peerviewpress.com/oncology/PA05278FCn200.mp3 Fri, 19 Dec 2008 10:29:42 -0500 Science, Medicine no 00:19:28 RCC, mTOR, everolimus, temsirolimus, deforolimus, renal cell, VEGF, sorafenib, bevacizumab, targeted therapy PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA05278FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA05278FCCMEinfo.pdf Fri, 19 Dec 2008 10:29:38 -0500 Science, Medicine no 00:00:00 RCC, mTOR, everolimus, temsirolimus, deforolimus, renal cell, VEGF, sorafenib, bevacizumab, targeted therapy PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, an expert in liver diseases discusses clinical issues and the latest evidence in the treatment of hepatocellular carcinoma. http://podcast.peerviewpress.com/oncology/PA04901FCp145.mp3 http://podcast.peerviewpress.com/oncology/PA04901FCp145_2.mp3 Mon, 13 Oct 2008 12:48:26 -0400 Science, Medicine no 00:43:42 TACE, HCC, liver cancer, sorafenib, bevacizumab, Child Pugh Turcotte, BCLC, ECOG PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04901FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04901FCCMEinfo_2.pdf Mon, 13 Oct 2008 12:47:26 -0400 Science, Medicine no 00:00:00 TACE, HCC, liver cancer, sorafenib, bevacizumab, Child Pugh Turcotte, BCLC, ECOG PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, an expert interprets the latest data on the treatment of advanced colorectal cancer (CRC) with a focus on the clinical implications of these data. Topics covered include the use of multiagent regimens, including combination therapy with biologics; the influence of biomarker testing on treatment selection; and the use of strategies to prevent premature treatment discontinuation, maximize efficacy, and minimize toxicity of current therapies. http://podcast.peerviewpress.com/oncology/PA04768FCn190.mp3 http://podcast.peerviewpress.com/oncology/PA04768FCn190.mp3 Wed, 17 Sep 2008 09:13:54 -0400 Science, Medicine no 00:18:27 CRC, KRAS, EGFR, VEGF, bevacizumab, CAIRO, CRYSTAL, OPUS, calcium, magnesium, oxaliplatin PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04768FCn190CMECEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04768FCn190CMECEinfo.pdf Wed, 17 Sep 2008 09:13:54 -0400 Science, Medicine no 00:00:00 CRC, KRAS, EGFR, VEGF, bevacizumab, CAIRO, CRYSTAL, OPUS, calcium, magnesium, oxaliplatin PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, hematology and oncology experts discuss the development and use of epigenetic treatments in cancer. The 3 presentations cover the rationale for targeting epigenetic alterations in cancer, the development and mechanisms of therapies directed against epigenetic targets, and the efficacy and safety of currently available and emerging epigenetic agent classes in solid tumors and hematologic malignancies. http://podcast.peerviewpress.com/oncology/PA04834FCr399.mp3 http://podcast.peerviewpress.com/oncology/PA04834FCr399.mp3 Fri, 12 Sep 2008 11:56:58 -0400 Science, Medicine no 00:31:52 epigenetics, DNA methylation, lymphoma, myeloma, leukemia, MDS, vorinostat, bevacizumab, depsipeptide, HDAC inhibitor PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04834FCr399CMECEinformation.pdf http://podcast.peerviewpress.com/oncology/PA04834FCr399CMECEinformation.pdf Fri, 12 Sep 2008 11:55:58 -0400 Science, Medicine no 00:00:00 epigenetics, DNA methylation, lymphoma, myeloma, leukemia, MDS, vorinostat, bevacizumab, depsipeptide, HDAC inhibitor PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, an expert provides a clinical update on the latest data on molecularly targeted therapies in advanced lung cancer. New strategies with currently approved targeted agents are assessed, and the ongoing exploration of investigational therapies is underscored. http://podcast.peerviewpress.com/oncology/PA04787FCn189.mp3 http://podcast.peerviewpress.com/oncology/PA04787FC_n189.mp3 Tue, 19 Aug 2008 14:34:08 -0400 Science no 00:23:39 ASCO, NSCLC, lung cancer, EGFR, erlotinib, bevacizumab, cetuximab, gefitinib, adenocarcinoma, squamous PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04787FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04787FCCMEinfo.pdf Tue, 19 Aug 2008 14:34:08 -0400 Science no 00:00:00 ASCO, NSCLC, lung cancer, EGFR, erlotinib, bevacizumab, cetuximab, gefitinib, adenocarcinoma, squamous PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts discuss currently available and emerging immunotherapies for melanoma, with a focus on adjuvant interferon therapy, vaccine strategies, and CTLA-4 antagonists. Recent clinical trial results are reviewed, and the role, benefits, and limitations of the various immunotherapeutic approaches are debated. http://podcast.peerviewpress.com/oncology/PA04363FCe012.mp3 http://podcast.peerviewpress.com/oncology/PA04363FCe012.mp3 Fri, 08 Aug 2008 11:13:10 -0400 Science no 00:40:50 CTLA-4 antagonists, melanoma, autoimmunity, interferon alpha, immunotherapy, CD40, T cell PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04363FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04363FCCMEinfo.pdf Fri, 08 Aug 2008 11:13:05 -0400 Science no 00:00:00 CTLA-4 antagonists, melanoma, autoimmunity, interferon alpha, immunotherapy, CD40, T cell PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts provide an update on novel immunotherapies under evaluation in melanoma, with a focus on anti–CTLA-4 antibodies. The benefits and limitations of currently available standard therapies are described, as well as the need for novel therapies. Efficacy and safety of the CTLA-4 antagonists are discussed, and whether or not the conventional clinical trial endpoints are appropriate for evaluating benefit from such therapies is debated. Additionally, the toxicity profile of the CTLA-4 antagonists and management of the key adverse effects associated with these agents are reviewed. http://podcast.peerviewpress.com/oncology/PA04362FC018.mp3 http://podcast.peerviewpress.com/oncology/PA04362FC018.mp3 Wed, 30 Jul 2008 14:36:41 -0400 Science, Medicine no 00:38:25 CTLA-4 antagonists, temozolomide, dacarbazine, Darthmouth regimen, melanoma PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04362FC018.pdf http://podcast.peerviewpress.com/oncology/PA04362FC018CMECEinfo.pdf Wed, 30 Jul 2008 14:35:41 -0400 Science, Medicine no 00:00:00 CTLA-4 antagonists, temozolomide, dacarbazine, Darthmouth regimen, melanoma PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts review current perspectives on drug resistance, appropriate patient monitoring, and molecular and mutational testing in managing patients with chronic myeloid leukemia (CML). Additionally, the rationale and potential for using treatment tailored to an individual patient with CML is discussed. http://podcast.peerviewpress.com/oncology/PA04835FCr398.mp3 http://podcast.peerviewpress.com/oncology/PA04835FCr398.mp3 Mon, 28 Jul 2008 14:13:19 -0400 Science, Medicine no 00:35:00 CML, BCR-ABL, tryrosine kinase, imatinib, nilotinib, dasatinib, T31FI mutation, decitabine PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04835FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04835FCCMEinfo.pdf Mon, 28 Jul 2008 14:13:16 -0400 Science, Medicine no 00:00:00 CML, BCR-ABL, tryrosine kinase, imatinib, nilotinib, dasatinib, T31FI mutation, decitabine PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this educational program, an expert describes the unique safety profile of the antiangiogenic agents in lung cancer, and discusses how to manage some of the key toxicities. http://podcast.peerviewpress.com/oncology/PA04435FCn180.mp3 http://podcast.peerviewpress.com/oncology/PA04435FCn180.mp3 Thu, 12 Jun 2008 10:20:06 -0400 Science no 00:21:39 antiangiogenesis, NSCLC, cytotoxics, bevacizumab, febrile neutropenia, sunitinib, sorafenib, vandetanib, toxicities PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04435FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04435FCCMEinfo.pdf Thu, 12 Jun 2008 10:20:03 -0400 Science no 00:00:00 antiangiogenesis, NSCLC, cytotoxics, bevacizumab, febrile neutropenia, sunitinib, sorafenib, vandetanib, toxicities PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts discuss the latest perspectives on the treatment of ovarian cancer. Benefits and limitations of current therapies for recurrent ovarian cancer are evaluated, and clinical issues related to management of this disease are debated. Additionally, the emerging role of novel targeted and cytotoxic therapies is reviewed. http://podcast.peerviewpress.com/oncology/PA04241FCe017.mp3 http://podcast.peerviewpress.com/oncology/PA04241FCe017.mp3 Fri, 06 Jun 2008 10:38:39 -0400 Science no 00:25:52 CA-125, liposomal doxorubicin, topotecan, capecitabine, ovarian cancer, gemcitabine, bevacizumab, EGFR PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04241FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04241FCCMEinfo.pdf Fri, 06 Jun 2008 10:38:37 -0400 Science no 00:00:00 CA-125, liposomal doxorubicin, topotecan, capecitabine, ovarian cancer, gemcitabine, bevacizumab, EGFR PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, an expert in breast cancer highlights latest clinical trial data, focusing on the role of more established as well as novel biologic therapies in early stage and advanced breast cancer in the context of a move towards more individualized therapy. http://podcast.peerviewpress.com/oncology/PA04346FCn181.mp3 http://podcast.peerviewpress.com/oncology/PA04346FCn181.mp3 Tue, 27 May 2008 16:56:42 -0400 Science no 00:33:34 antiangiogenic, HER2, bevacizumab, VEGF, SABCS, metastatic breast cancer, trastuzumab PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04346FCCME.pdf http://podcast.peerviewpress.com/oncology/PA04346FCCMEinfo.pdf Tue, 27 May 2008 16:56:38 -0400 Science no 00:00:00 antiangiogenic, HER2, bevacizumab, VEGF, SABCS, metastatic breast cancer, trastuzumab PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts provide an update on the antineoplastic resistance mechanisms in breast cancer and possible strategies for combating resistance. Through an interactive discussion, resistance mechanisms that have potential clinical relevance are summarized, and treatment options for overcoming or circumventing resistance, including the role of epothilones, are reviewed. In addition, clinical data and practical considerations for use of epothilones in metastatic breast cancer are discussed. http://podcast.peerviewpress.com/oncology/PA04156FCe010.mp3 http://podcast.peerviewpress.com/oncology/PA04156FCe010.mp3 Wed, 23 Apr 2008 13:58:12 -0400 Science no 00:27:43 MBC, epothilones, ixabepilone, chemotherapy, P-glycoprotein, monoclonal antibodies, paclitaxel, sagopilone PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04156FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04156FCCMEinfo.pdf Wed, 23 Apr 2008 13:58:12 -0400 Science no 00:00:00 MBC, epothilones, ixabepilone, chemotherapy, P-glycoprotein, monoclonal antibodies, paclitaxel, sagopilone PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME/CE activity, experts in oncology highlight latest evidence in advanced/metastatic colorectal cancer (CRC). Latest efficacy and safety data on targeted therapies are reviewed, strategies for optimal use of currently available therapies in unresectable metastatic CRC are discussed, the evolving role of predictive and prognostic molecular markers is assessed, and current concepts and issues in the treatment of resectable metastatic CRC are described. http://podcast.peerviewpress.com/oncology/PA04432FCs469.mp3 http://podcast.peerviewpress.com/oncology/PA04432FCs469.mp3 Fri, 11 Apr 2008 09:07:48 -0400 Science no 00:18:29 mCRC, EGFR, KRAS, ASCO-GI, FOLFIRI, oxaliplatin, BRiTE PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04432FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04423FCCMEinfo.pdf Fri, 11 Apr 2008 09:07:47 -0400 Science no 00:00:00 mCRC, EGFR, KRAS, ASCO-GI, FOLFIRI, oxaliplatin, BRiTE PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in breast cancer discuss new data on targeted therapies in early stage and advanced/metastatic breast cancer. http://podcast.peerviewpress.com/oncology/PA04112FCs450.mp3 http://podcast.peerviewpress.com/oncology/PA04112FCs450.mp3 Tue, 01 Apr 2008 11:49:02 -0400 Science no 00:41:08 HER2, SABCS, topo II, anthracycline, trastuzumab, recurrence score, bevacizumab PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04112FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04112FCCMEinfo_2.pdf Tue, 01 Apr 2008 11:48:02 -0400 Science, Medicine no 00:00:00 HER2, SABCS, topo II, anthracycline, trastuzumab, recurrence score, bevacizumab PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this case-based educational program, experts will discuss how to optimally use angiogensis inhibitors in treatment of advanced lung and colorectal malignancies, and use patient scenarios to illustrate how to manage common adverse effects in patients with these tumors receiving anti-VEGF therapy. http://podcast.peerviewpress.com/oncology/PA03473FC2p125.mp3 http://podcast.peerviewpress.com/oncology/PA03473FC2p125.mp3 Wed, 26 Mar 2008 16:18:11 -0400 Science no 00:27:34 NSCLC, CRC, VEGF, antiangiogenesis, bevacizumab, oxaliplatin, liver metastases PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03473FC2CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03473FC2CMEinfo.pdf Wed, 26 Mar 2008 16:17:13 -0400 Science no 00:00:00 NSCLC, CRC, VEGF, antiangiogenesis, bevacizumab, oxaliplatin, liver metastases PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, an expert in breast cancer highlights latest clinical trial data in breast cancer, focusing on the role of chemotherapy in early stage and advanced breast cancer in the context of a move towards more individualized therapy. http://podcast.peerviewpress.com/oncology/PA04309FCn178.mp3 http://podcast.peerviewpress.com/oncology/PA04309FCn178.mp3 Mon, 17 Mar 2008 16:53:37 -0400 Science no 00:23:58 Chemotherapy, HER2, trastuzumab, anthracycline, recurrence score, SABCS 2007, cytotoxics PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04309FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04309FCCMEinfo.pdf Mon, 17 Mar 2008 16:53:33 -0400 Science no 00:00:00 Chemotherapy, HER2, trastuzumab, anthracycline, recurrence score, SABCS 2007, cytotoxics PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this program, an expert will discuss clinical scenarios to illustrate how to optimally manage patients with metastatic colorectal cancer, with a specific focus on use of molecularly targeted biologic agents in the context of other available therapies. http://podcast.peerviewpress.com/oncology/PA03760FC1p121.mp3 http://podcast.peerviewpress.com/oncology/PA03760FC1p121.mp3 Fri, 14 Mar 2008 16:33:28 -0400 Science no 00:26:59 mCRC, systemic chemotherapy, FOLFOX, FOLFIRI, CAPOX, bevacizumab, oxaliplatin, 5-FU, leucovorin, EGFR, cetuximab PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03760FC1CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03760FC1CMEinfo.pdf Fri, 14 Mar 2008 16:32:28 -0400 Science no 00:00:00 mCRC, systemic chemotherapy, FOLFOX, FOLFIRI, CAPOX, bevacizumab, oxaliplatin, 5-FU, leucovorin, EGFR, cetuximab PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts provide an update on the current status and future directions in HER2 testing in breast cancer. Through an interactive discussion, the importance of accurate HER2 testing and the role of HER2 status as a predictive factor for HER2-targeted therapies are emphasized, current methods for HER2 testing and their benefits and limitations are assessed, and key recommendations for the latest ASCO-CAP HER2 testing guidelines are summarized. Furthermore, the experts describe some of the new molecular diagnostics, including multigene arrays, which are showing promise as better tools for determining HER2 status and predicting benefit from HER2-directed therapies. http://podcast.peerviewpress.com/oncology/PA03994FCe008.mp3 http://podcast.peerviewpress.com/InfectiousDiseases/PA03994FCe008.mp3 Thu, 21 Feb 2008 10:55:05 -0500 Science no 00:34:26 HER2, trastuzumab, breast cancer, FISH, IHC, immunohistochemistry, array, immunostain, cytology, HER2/CEP 17 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03994FCCMEinfo.pdf http://podcast.peerviewpress.com/InfectiousDiseases/PA03994FCCMEinfo.pdf Thu, 21 Feb 2008 10:54:06 -0500 Science no 00:00:00 HER2, trastuzumab, breast cancer, FISH, IHC, immunohistochemistry, array, immunostain, cytology, HER2/CEP 17 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in breast cancer discuss the optimal use of angiogenesis inhibitors. Recent clinical trial data on angiogenesis inhibitors are assessed; answers to common questions regarding the role of these agents are addressed; and patient scenarios are used to illustrate how to integrate anti-VEGF therapy into routine patient care. http://podcast.peerviewpress.com/oncology/PA03775FC2r349.mp3 http://podcast.peerviewpress.com/InfectiousDiseases/PA03775FC2r349.mp3 Mon, 18 Feb 2008 11:23:57 -0500 Science no 00:34:08 Angiogenesis, breast cancer, VEGF, HER2, ER, paclitaxel, zolendronate, bevacizumab, E2100, case studies, ECOG, toxicities, capecitabine, first-line treatment, targeted agents, docetaxel, axitinib, trastuzumab, progression-free survival, PFS PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03775FC2CMEinfo.pdf http://podcast.peerviewpress.com/InfectiousDiseases/PA03775FC2CMEinfo.pdf Mon, 18 Feb 2008 11:22:56 -0500 Science no 00:00:00 Angiogenesis, breast cancer, VEGF, HER2, ER, paclitaxel, zolendronate, bevacizumab, E2100, case studies, ECOG, toxicities, capecitabine, first-line treatment, targeted agents, docetaxel, axitinib, trastuzumab, progression-free survival, PFS PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts in the treatment of CML and Ph+ acute lymphoblastic leukemia discuss recent data on the role of targeted agents in the treatment of these diseases. An emphasis is placed on the second generation of targeted agents that are available for treatment of patients who develop imatinib resistance or intolerance. The mechanisms for developing resistance are also reviewed. http://podcast.peerviewpress.com/oncology/PA03938FCe006.mp3 http://podcast.peerviewpress.com/oncology/PA03938FCe006.mp3 Thu, 14 Feb 2008 16:29:38 -0500 Science no 01:05:05 oncology, hematology, chronic myeloid leukemia CML, targeted therapies, resistance, tyrosine kinase inhibitors, chemotherapy, imatinib, dasatinib, nilotinib, mutations, bosutinib, MK-0457 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03938FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03938FCCMEinfo.pdf Thu, 14 Feb 2008 16:29:33 -0500 Science no 00:00:00 oncology, hematology, chronic myeloid leukemia CML, targeted therapies, resistance, tyrosine kinase inhibitors, chemotherapy, imatinib, dasatinib, nilotinib, mutations, bosutinib, MK-0457 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this program, an expert will discuss clinical scenarios to illustrate how to optimally manage patients with early stage colorectal cancer, with a focus on appropriate selection of adjuvant therapy for patients with stage II and III disease, and the emerging role of novel therapies and prognostic/predictive markers. http://podcast.peerviewpress.com/oncology/PA03760FC2p128.mp3 http://podcast.peerviewpress.com/oncology/PA03760FC2p128.mp3 Mon, 11 Feb 2008 16:56:01 -0500 Science no 00:26:35 Colon, colorectal, oxaliplatin, 5-FU/LV, FOLFOX, FOLFOX4, capecitabine, fluoropyrimidine, CAPOX, bevacizumab, cetuximab, EGFR, capecitabine, FOLFOX6 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03760FC2CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03760FC2CMEinfo.pdf Mon, 11 Feb 2008 16:55:56 -0500 Science no 00:00:00 Colon, colorectal, oxaliplatin, 5-FU/LV, FOLFOX, FOLFOX4, capecitabine, fluoropyrimidine, CAPOX, bevacizumab, cetuximab, EGFR, capecitabine, FOLFOX6 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, an expert in breast cancer discusses goals and challenges in the management of metastatic breast cancer, and how these goals can be best met through individualized therapy. http://podcast.peerviewpress.com/oncology/PA03916FCn172.mp3 http://podcast.peerviewpress.com/oncology/PA03916FCn172.mp3 Wed, 23 Jan 2008 15:53:13 -0500 Science no 00:22:32 Metastatic breast cancer, MBC, bevacizumab, anthracyclines, overall survival, progression-free survival, response rate, gemcitabine, paclitaxel, vinorelbine, ixabepilone, cytotoxic. PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03916FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03916FCCMEinfo.pdf Wed, 23 Jan 2008 15:53:07 -0500 Science no 00:00:00 Metastatic breast cancer, MBC, bevacizumab, anthracyclines, overall survival, progression-free survival, response rate, gemcitabine, paclitaxel, vinorelbine, ixabepilone, cytotoxic. PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME program, an expert in the treatment of renal cell carcinoma discusses advances in the use of targeted therapies in the management of this disease in a case-based format. http://podcast.peerviewpress.com/oncology/PA04017FCn174.mp3 http://podcast.peerviewpress.com/oncology/PA04017FCn174.mp3 Mon, 21 Jan 2008 16:55:48 -0500 Science no 00:14:18 renal cell carcinoma, renal cell cancer, RCC, metastatic RCC, advanced RCC, targeted therapies, tyrosine kinase inhibitors, TKIs, IL-2, sunitinib, sorafenib, bevacizumab, temsirolimus, IFN-α, Memorial Sloan-Kettering Cancer Center (MSKCC) system PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04017FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04017FCCMEinfo.pdf Mon, 21 Jan 2008 16:54:49 -0500 Science no 00:00:00 renal cell carcinoma, renal cell cancer, RCC, metastatic RCC, advanced RCC, targeted therapies, tyrosine kinase inhibitors, TKIs, IL-2, sunitinib, sorafenib, bevacizumab, temsirolimus, IFN-α, Memorial Sloan-Kettering Cancer Center (MSKCC) system PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts in the treatment of colorectal cancer present recent data on the efficacy and safety of targeted agents in the management of advanced disease. Strategies for integration of these agents into treatment plans are also highlighted. http://podcast.peerviewpress.com/oncology/PA04093FCs443.mp3 http://podcast.peerviewpress.com/oncology/PA04093FCs443.mp3 Thu, 20 Dec 2007 15:41:54 -0500 Science no 00:25:28 Biologics, mCRC, CRC, metastatic, colorectal, cancer, biologics, cytotoxic, panitumumab, erlotinib, bevacizumab, VEGF, EGRF PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04093FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04093FCCMEinfo.pdf Thu, 20 Dec 2007 15:41:48 -0500 Science no 00:00:00 Biologics, mCRC, CRC, metastatic, colorectal, cancer, biologics, cytotoxic, panitumumab, erlotinib, bevacizumab, VEGF, EGRF PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts review latest evidence on antiangiogenic therapies in breast cancer. Different ways to target angiogenesis in breast cancer are described, and recent data from studies evaluating angiogenesis inhibitors with cytotoxic and other targeted agents in breast cancer are discussed. http://podcast.peerviewpress.com/oncology/PA03775FC1r348.mp3 http://podcast.peerviewpress.com/oncology/PA03775FC1r348.mp3 Wed, 12 Dec 2007 15:59:46 -0500 Science no 00:31:20 Breast cancer, bevacizumab, trastuzumab, angiogenesis inhibition, antiangiogenic therapy, targeted therapy, biologics, VEGF, HER2 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03775FC1CMECEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03775FC1CMECEinfo.pdf Wed, 12 Dec 2007 15:59:43 -0500 Science no 00:00:00 Breast cancer, bevacizumab, trastuzumab, angiogenesis inhibition, antiangiogenic therapy, targeted therapy, biologics, VEGF, HER2 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts will present an overview of key clinical data on antiangiogenic therapies in solid tumors and discuss practical aspects related to using these agents in routine patient care. Particular attention will be paid to adverse events associated with use of the anti-VEGF agents in colorectal, lung, and breast cancer, and recommendations for the management of common toxicities will be provided. http://podcast.peerviewpress.com/oncology/PA03473FC1r316.mp3 http://podcast.peerviewpress.com/oncology/PA03473FC1r316.mp3 Mon, 26 Nov 2007 17:18:19 -0500 Science no 00:53:21 Bevacizumab, angiogenisis, angiogenic therapy, VEGF, ECOG 4599, AVF2107, ECOG 3200, NO16966, FOLFOX, XELOX, ECOG 2100, sunitinib, AVOREN, EGFR PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03473FC1CMECEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03473FC1CMECEinfo.pdf Mon, 26 Nov 2007 17:18:16 -0500 Science no 00:00:00 Bevacizumab, angiogenisis, angiogenic therapy, VEGF, ECOG 4599, AVF2107, ECOG 3200, NO16966, FOLFOX, XELOX, ECOG 2100, sunitinib, AVOREN, EGFR PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, an expert discusses optimal treatment of operable and inoperable pancreatic cancer based on relevant case scenarios. http://podcast.peerviewpress.com/oncology/PA03788FCp126.mp3 http://podcast.peerviewpress.com/oncology/PA03788FCp126.mp3 Fri, 16 Nov 2007 16:33:08 -0500 Science no 00:34:11 Pancreatic cancer, pancreas, adjuvant chemotherapy, resectable, unresectable, operable, inoperable, targeted therapies, biologics, gemcitabine, bevacizumab, cetuximab, erlotinib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03788FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03788FCCMEinfo.pdf Fri, 16 Nov 2007 16:33:04 -0500 Science no 00:00:00 Pancreatic cancer, pancreas, adjuvant chemotherapy, resectable, unresectable, operable, inoperable, targeted therapies, biologics, gemcitabine, bevacizumab, cetuximab, erlotinib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. This case-based program describes three clinical situations illustrating the identification and management of patients with cancer and risk for VTE. http://podcast.peerviewpress.com/oncology/PA03702FCp129.mp3 http://podcast.peerviewpress.com/InfectiousDiseases/PA03702FCp129.mp3 Thu, 15 Nov 2007 17:04:38 -0500 Science no 00:50:25 Venous thromboembolism, cancer, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, anticoagulants, Thrombolytic therapy, heparin, warfarin, breast cancer, prostate cancer, colorectal cancer, surgery PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03702FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03702FCCMEinfo.pdf Thu, 15 Nov 2007 17:04:37 -0500 Science no 00:00:00 Venous thromboembolism, cancer, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, anticoagulants, Thrombolytic therapy, heparin, warfarin, breast cancer, prostate cancer, colorectal cancer, surgery PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, an expert discusses treatment of advanced NSCLC, with a main focus on optimal integration of targeted agents into standard therapy for this disease. http://podcast.peerviewpress.com/oncology/PA03645FCp123.mp3 http://podcast.peerviewpress.com/InfectiousDiseases/PA03645FCp123.mp3 Fri, 26 Oct 2007 15:00:35 -0400 Science no 00:27:49 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, Tarceva, bevacizumab, Avastin, sunitinib, sorafenib, gefitinib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03645FCCMEinfo.pdf http://podcast.peerviewpress.com/InfectiousDiseases/PA03645FCCMEinfo.pdf Fri, 26 Oct 2007 15:00:35 -0400 Science no 00:00:00 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, Tarceva, bevacizumab, Avastin, sunitinib, sorafenib, gefitinib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, an expert discusses treatment of early stage HER2-positive breast cancer based on relevant case scenarios, with a main focus on optimal use of HER2-targeted therapy in the context of other available treatment options. http://podcast.peerviewpress.com/oncology/PA03486FCp120.mp3 http://podcast.peerviewpress.com/oncology/PA03486FCp120.mp3 Thu, 18 Oct 2007 15:59:50 -0400 Science no 00:26:02 HER2, breast cancer, HER2-targeted therapy, HER2 testing, trastuzumab, Herceptin, NSABP B31, NCCTG 9831, HERA, BCIRG 006 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03486FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03486FCCMEinfo.pdf Thu, 18 Oct 2007 15:59:43 -0400 Science no 00:00:00 HER2, breast cancer, HER2-targeted therapy, HER2 testing, trastuzumab, Herceptin, NSABP B31, NCCTG 9831, HERA, BCIRG 006 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts present current data on antiangiogenic therapies in metastatic breast cancer (MBC). Clinical relevance of the endpoints used with cytostatic targeted agents and cytotoxic chemotherapeutics in MBC is evaluated. Recent efficacy and safety data from studies evaluating antiangiogenic therapies in advanced disease are summarized and interpreted, and practical recommendations for optimal integration of angiogenesis inhibitors into the treatment of MBC are provided. http://podcast.peerviewpress.com/oncology/PA03499FCr330.mp3 http://podcast.peerviewpress.com/InfectiousDiseases/PA03499FCr330.mp3 Thu, 27 Sep 2007 10:14:51 -0400 Science no 00:31:29 Breast cancer, MBC, VEGF, antiangiogenic, ECOG 2100, bevacizumab, Avastin, angiogenesis inhibitors, tyrosine kinase inhibitors PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03499FCCMEinfo.pdf http://podcast.peerviewpress.com/InfectiousDiseases/PA03499FCCMEinfo.pdf Thu, 27 Sep 2007 10:14:50 -0400 Science no 00:00:00 Breast cancer, MBC, VEGF, antiangiogenic, ECOG 2100, bevacizumab, Avastin, angiogenesis inhibitors, tyrosine kinase inhibitors PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in the treatment of lung cancer present the most current data on molecularly targeted agents in the treatment of NSCLC. Efficacy and safety of anti-VEGF, anti-EGFR, and other novel targeted therapies will be discussed. The experts will also focus on the evolving role of predictive and prognostic markers and the importance of developing such tools that could assist clinicians in selecting optimal therapy for each individual patient with lung cancer. http://podcast.peerviewpress.com/oncology/PA03774FC2s410.mp3 http://podcast.peerviewpress.com/oncology/PA03774FCs410.mp3 Tue, 25 Sep 2007 12:53:57 -0400 Science no 00:39:34 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, Tarceva, bevacizumab, Avastin, ASCO, sunitinib, sorafenib, gefitinib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03774FC2CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03774FC2CMEinfo.pdf Tue, 25 Sep 2007 12:52:54 -0400 Science no 00:00:00 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, Tarceva, bevacizumab, Avastin, ASCO, sunitinib, sorafenib, gefitinib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this program, experts present up-to-date information on treatment of advanced or metastatic NSCLC. Options for first-, second-, and third-line treatment are discussed, and factors that influence treatment decisions in these settings are assessed. http://podcast.peerviewpress.com/oncology/PA03912FCs323.mp3 http://podcast.peerviewpress.com/oncology/PA03912FCs323.mp3 Thu, 20 Sep 2007 16:04:06 -0400 Science no 00:23:50 NSCLC, lung cancer, chemotherapy, targeted therapy, alternative treatments, gemcitabine, pemetrexed, bevacizumab, erlotinib, treatment selection, individualized treatment, ASCO, NCCN PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03912FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03912FCCMEinfo.pdf Thu, 20 Sep 2007 16:04:02 -0400 Science no 00:00:00 NSCLC, lung cancer, chemotherapy, targeted therapy, alternative treatments, gemcitabine, pemetrexed, bevacizumab, erlotinib, treatment selection, individualized treatment, ASCO, NCCN PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts in lung cancer discuss the current and evolving role of molecularly targeted therapies in NSCLC. Clinical data on anti-VEGF and anti-EGFR therapies are assessed, and practical considerations for optimal integration of these agents into standard treatment for NSCLC are discussed. Unanswered questions regarding the role of targeted therapies and future research directions are described as well. http://podcast.peerviewpress.com/oncology/PA03774FC1r315.mp3 http://podcast.peerviewpress.com/oncology/PA03774FC1r315.mp3 Wed, 12 Sep 2007 11:00:59 -0400 Science no 00:36:58 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, bevacizumab, Avastin PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03774FC1CMECEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03774FC1CMECEinfo.pdf Wed, 12 Sep 2007 11:00:35 -0400 Science no 00:00:00 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, bevacizumab, Avastin PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts in the treatment of hepatocellular carcinoma (HCC) discuss recent data on the efficacy and safety of emerging biologically driven agents in this condition. The recent data on staging systems and classification systems for HCC are also reviewed and the molecular targets in HCC are discussed. http://podcast.peerviewpress.com/oncology/PA04009FCs413.mp3 http://podcast.peerviewpress.com/oncology/PA04009FCs413.mp3 Fri, 24 Aug 2007 18:35:21 -0400 Science no 00:38:27 hepatocellular carcinoma, advanced hepatocellular carcinoma, HCC, targeted agents, biologic agents, staging systems, hepatitis B, hepatitis, C, cirrhosis, transplantation, chemotherapy, sorafenib, cetuximab, sunitinib, bevacizumab, erlotinib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04009FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04009FCCMEinfo.pdf Fri, 24 Aug 2007 18:34:38 -0400 Science no 00:00:00 hepatocellular carcinoma, advanced hepatocellular carcinoma, HCC, targeted agents, biologic agents, staging systems, hepatitis B, hepatitis, C, cirrhosis, transplantation, chemotherapy, sorafenib, cetuximab, sunitinib, bevacizumab, erlotinib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this panel discussion, experts present up-to-date data on antiangiogenic therapies in breast cancer. Recent clinical data on antiangiogenic therapy in metastatic breast cancer are reviewed, and implications for clinical practice and research are discussed. The potential benefits of targeting multiple pathways in breast cancer, by using a combination of antiangiogenic and other biologic agents or novel multitargeted therapies with antiangiogenic properties, are described. As well, strategies for optimal integration of antiangiogenic agents into treatment of breast cancer in the context of other cytotoxic and biologic therapies are discussed. http://podcast.peerviewpress.com/oncology/PA03257FC3e004.mp3 http://podcast.peerviewpress.com/oncology/PA03257FC3e004.mp3 Thu, 23 Aug 2007 09:27:50 -0400 Science no 00:46:02 Breast cancer, angiogenesis inhibition, antiangiogenic therapy, VEGF, HER2, bevacizumab, trastuzumab, sunitinib, axitinib, targeted therapy, biologics, SABCS, ASCO PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03257FC3CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03257FC3CMEinfo.pdf Thu, 23 Aug 2007 09:27:11 -0400 Science no 00:00:00 Breast cancer, angiogenesis inhibition, antiangiogenic therapy, VEGF, HER2, bevacizumab, trastuzumab, sunitinib, axitinib, targeted therapy, biologics, SABCS, ASCO PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts in the treatment of advanced renal cell carcinoma discuss recent data on the efficacy and safety of current and emerging targeted agents and combinations in this condition. Dosing concerns and patient selection are also highlighted. http://podcast.peerviewpress.com/oncology/PA03777FCs407.mp3 http://podcast.peerviewpress.com/oncology/PA03777FCs407.mp3 Wed, 22 Aug 2007 15:32:29 -0400 Science no 00:30:24 renal cell carcinoma, renal cell cancer, RCC, metastatic RCC, advanced RCC, targeted therapies, tyrosine kinase inhibitors, TKIs, IL-2, sunitinib, sorafenib, bevacizumab, temsirolimus, erlotinib, IFN-α, UCLA Integrated Staging System, Von Hippel Lindau PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03777FCs407CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03777FCs407CMEinfo.pdf Wed, 22 Aug 2007 15:32:17 -0400 Science no 00:00:00 renal cell carcinoma, renal cell cancer, RCC, metastatic RCC, advanced RCC, targeted therapies, tyrosine kinase inhibitors, TKIs, IL-2, sunitinib, sorafenib, bevacizumab, temsirolimus, erlotinib, IFN-α, UCLA Integrated Staging System, Von Hippel Lindau PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts present up-to-date data on molecularly targeted therapies in metastatic colorectal cancer (CRC). The impact and expanding role of targeted agents in the treatment of metastatic CRC are reviewed, and latest efficacy and safety data biologics in the context of other available therapies, as well as the potential implications for clinical practice, are assessed. Furthermore, important clinical questions/issues related to treatment of advanced disease are discussed, and strategies for optimal use of all the available agents in the treatment of patients with metastatic CRC are proposed. http://podcast.peerviewpress.com/oncology/PA03759FCs409.mp3 http://podcast.peerviewpress.com/oncology/PA03759FCs409_2.mp3 Wed, 15 Aug 2007 16:45:44 -0400 Science no 00:31:45 Colorectal cancer, targeted therapy, biologic therapy, bevacizumab, Avastin, cetuximab, Erbitux, panitumumab, vascular endothelial growth factor, VEGF, EGFR, epidermal growth factor receptor, ASCO 2007 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03759FCs409.pdf http://podcast.peerviewpress.com/oncology/PA03759FCs409.pdf Wed, 15 Aug 2007 16:45:16 -0400 Science no 00:00:00 Colorectal cancer, targeted therapy, biologic therapy, bevacizumab, Avastin, cetuximab, Erbitux, panitumumab, vascular endothelial growth factor, VEGF, EGFR, epidermal growth factor receptor, ASCO 2007 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts provide an overview of recent progress in the treatment of breast cancer, focusing on the evolving role of molecularly targeted therapies. Current clinical data on HER2- and VEGF-targeted agents in the treatment of early stage and metastatic breast cancer are summarized, and the clinical implications of these data are assessed. Furthermore, clinical issues related to optimal use of HER2- and VEGF-targeted therapies in the treatment of breast cancer are discussed. Lastly, some of the new and ongoing studies evaluating the targeted agents are reviewed, as well as novel molecularly targeted therapies currently under investigation in breast cancer. http://podcast.peerviewpress.com/oncology/PA03257FC5r338.mp3 http://podcast.peerviewpress.com/oncology/PA03257FC5r338.mp3 Fri, 03 Aug 2007 14:03:29 -0400 Science no 00:54:34 Breast cancer, VEGF, HER2, bevacizumab, trastuzumab, lapatinib, angiogenesis inhibition, antiangiogenic therapy, targeted therapy, biologics, SABCS, ASCO PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03257FC5CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03257FC5CMEinfo.pdf Fri, 03 Aug 2007 14:03:13 -0400 Science no 00:00:00 Breast cancer, VEGF, HER2, bevacizumab, trastuzumab, lapatinib, angiogenesis inhibition, antiangiogenic therapy, targeted therapy, biologics, SABCS, ASCO PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts in the management of CML discuss current and emerging targeted therapies for this condition. Mechanisms for the development and monitoring of resistance are also reviewed. http://podcast.peerviewpress.com/oncology/PA03826FCr320.mp3 http://podcast.peerviewpress.com/oncology/PA03826FCr320.mp3 Thu, 12 Jul 2007 14:55:12 -0400 Science no 00:25:19 oncology, hematology, acute lymphocytic leukaemia, chronic myeloid leukaemia, CML, targeted therapies, tyrosine kinase inhibitors, chemotherapy, imatinib, dasatinib, nilotinib, resistance monitoring, mutations, bosutinib, MK-0457 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03826FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03826FCCMEinfo.pdf Thu, 12 Jul 2007 14:54:55 -0400 Science no 00:00:00 oncology, hematology, acute lymphocytic leukaemia, chronic myeloid leukaemia, CML, targeted therapies, tyrosine kinase inhibitors, chemotherapy, imatinib, dasatinib, nilotinib, resistance monitoring, mutations, bosutinib, MK-0457